Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1-linked immunochemotherapy resistance in NSCLC via microbial metabolites.
Cuijiao Feng, Guangqi Gao, Qiuwen He et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the effects of Bifidobacterium animalis subsp. lactis V9 on immunochemotherapy resistance in patients with advanced non-small cell lung cancer (NSCLC) linked to elevated serum CYFRA 21-1. The study found that adjunctive B. lactis V9 improved the objective response rate to 47% compared to 33% in the placebo group, indicating a potential strategy to overcome treatment resistance associated with gut dysbiosis.
Key findings
- Adjunctive B. lactis V9 resulted in a 47% objective response rate compared to 33% in the placebo group.
- The disease control rate was 87% for B. lactis V9 versus 67% for placebo.
- Responders exhibited enriched B. animalis and elevated quinaldic acid/catechol levels.
Why it matters
Understanding the relationship between gut microbiota and treatment efficacy can help clinicians identify potential interventions to enhance immunotherapy outcomes in patients with NSCLC, particularly those exhibiting treatment resistance.